Akwasi Boateng, MD
Urology · East Brunswick, NJNPI 1144541996
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 50.7% of the total. Reporting peaked in 2020 at $1,718 and has fallen 81.5% since, to $319 in 2025.
Across 94 payments — averaging $32.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$2K
- Davol Inc.$298
- Johnson & Johnson$297
- Pfizer$227
- Astellas Pharma US Inc$172
- Bayer$105
- plus $420 from 13 others
Across 4 payments — averaging $6250.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$25K
What the payments were for
- Consulting fees$1,32543%
- Speaking & faculty fees$502%
- Food & beverage$1,59352%
- Education$1104%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 20 | $1,559 |
| Davol Inc. | 2 | $298 |
| Johnson & Johnson | 21 | $297 |
| Pfizer | 17 | $227 |
| Astellas Pharma US Inc | 8 | $172 |
| Bayer | 6 | $105 |
| Procept Biorobotics Corporation | 1 | $90 |
| AstraZeneca | 5 | $78 |
| Valencia Technologies Corporation | 1 | $50 |
| Boston Scientific | 2 | $37 |
| Urogen Pharma, Inc. | 2 | $35 |
| AbbVie | 2 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Urovant Sciences Inc | 1 | $15 |
| Merck | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,079 in reported general payments places this provider in the 60th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 17 | $243,875 |
| MyrbetriqMirabegron | 243 | $197,159 |
| Abiraterone Acetate | 26 | $121,899 |
| GemtesaVibegron | 37 | $33,198 |
| Methenamine Hippurate | 97 | $9,221 |
| Tamsulosin Hcl | 579 | $8,482 |
| Mirabegron ErMirabegron | 16 | $7,605 |
| Silodosin | 90 | $6,786 |
| Finasteride | 435 | $6,275 |
| Oxybutynin Chloride ErOxybutynin Chloride | 159 | $4,386 |
| Trospium Chloride ErTrospium Chloride | 25 | $3,191 |
| NitrofurantoinNitrofurantoin Macrocrystal | 64 | $2,062 |
| Dutasteride | 38 | $1,736 |
| Estradiol | 17 | $1,732 |
| Solifenacin Succinate | 19 | $1,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $297 | $243,87517 claims |
| Astellas Pharma US IncMyrbetriq | $172 | $197,159243 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $14 | $121,89926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 401 urology providers in New Jersey.
Other urology in East Brunswick
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.